Home / Research library / Peptide clinical trials
Peptide clinical trials tracker
Yes. PeptideTech has matched 853 ClinicalTrials.gov registrations across 54 tracked compounds in which the compound is a listed intervention; 287 are active or recruiting, 319 are phase 3 or 4, and 130 have posted results. Profiles with the most active registrations: Tirzepatide (38), Semaglutide (34), Mazdutide (24), Cagrilintide (16) and Eloralintide (15). A registration describes a protocol, not an outcome, and studies of an approved medicine do not concern research-labelled listings.
- Registrations
- 853
- Compounds
- 54
- Active or recruiting
- 287
- Phase 3 or 4
- 319
- With posted results
- 130
Registry fields checked October 9, 2026 through the ClinicalTrials.gov API · registry facts only, never outcomes
Registered trials by compound
| Compound | Matched | Active | By highest phase | Lead sponsors | Human studies (PubMed) |
|---|---|---|---|---|---|
| TirzepatideCompare research listing prices → | 38 | 38 | Phase 4: 9 · Phase 3: 6 · Phase 2: 14 · Phase 1: 2 · Early phase 1: 1 · Not applicable: 6 | Eli Lilly and Company; Yunlong Wang | 7 |
| SemaglutideCompare research listing prices → | 34 | 34 | Phase 4: 8 · Phase 3: 12 · Phase 2: 2 · Phase 1: 2 · Early phase 1: 1 · Not applicable: 9 | Mayo Clinic; Novo Nordisk A/S | 5 |
| MazdutideCompare research listing prices → | 40 | 24 | Phase 4: 5 · Phase 3: 11 · Phase 2: 12 · Phase 1: 5 · Not applicable: 7 | Innovent Biologics (Suzhou) Co. Ltd.; Eli Lilly and Company | 6 |
| CagrilintideCompare research listing prices → | 40 | 16 | Phase 3: 19 · Phase 2: 4 · Phase 1: 17 | Novo Nordisk A/S | 4 |
| Eloralintide | 22 | 15 | Phase 3: 5 · Phase 2: 5 · Phase 1: 12 | Eli Lilly and Company | 3 |
| TriptorelinCompare research listing prices → | 29 | 12 | Phase 4: 8 · Phase 3: 13 · Phase 2: 5 · Early phase 1: 1 · Not applicable: 2 | Ipsen; Damascus University | 2 |
| GlutathioneCompare research listing prices → | 37 | 11 | Phase 4: 1 · Phase 3: 4 · Phase 2: 5 · Phase 1: 7 · Early phase 1: 1 · Not applicable: 19 | Adia Med of Winter Park LLC; Cairo University | 3 |
| OxytocinCompare research listing prices → | 36 | 11 | Phase 4: 6 · Phase 3: 3 · Phase 2: 9 · Phase 1: 3 · Early phase 1: 3 · Not applicable: 12 | University of Electronic Science and Technology of China; Cairo University | 4 |
| RetatrutideCompare research listing prices → | 34 | 11 | Phase 3: 14 · Phase 2: 4 · Phase 1: 15 · Not applicable: 1 | Eli Lilly and Company; Hudson Biotech | 7 |
| Thymosin Alpha-1Compare research listing prices → | 38 | 9 | Phase 4: 3 · Phase 3: 5 · Phase 2: 23 · Phase 1: 2 · Early phase 1: 1 · Not applicable: 4 | SciClone Pharmaceuticals; Sun Yat-sen University | 3 |
| SurvodutideCompare research listing prices → | 27 | 9 | Phase 3: 11 · Phase 2: 3 · Phase 1: 13 | Boehringer Ingelheim; University Medical Center Groningen | 6 |
| LiraglutideCompare research listing prices → | 33 | 5 | Phase 4: 10 · Phase 3: 8 · Phase 2: 2 · Phase 1: 3 · Not applicable: 10 | Novo Nordisk A/S; Beni-Suef University | 4 |
| SS-31Compare research listing prices → | 30 | 3 | Phase 4: 1 · Phase 3: 4 · Phase 2: 15 · Phase 1: 9 · Not applicable: 1 | Stealth BioTherapeutics Inc.; Children's Hospital of Philadelphia | 5 |
| TesamorelinCompare research listing prices → | 20 | 3 | Phase 4: 2 · Phase 3: 2 · Phase 2: 9 · Phase 1: 1 · Not applicable: 6 | Theratechnologies; Massachusetts General Hospital | 7 |
| BPC-157Compare research listing prices → | 3 | 2 | Phase 2: 1 · Phase 1: 2 | Hudson Biotech; PharmaCotherapia d.o.o. | 1 |
| Melanotan-1Compare research listing prices → | 23 | 1 | Phase 3: 6 · Phase 2: 13 · Phase 1: 3 · Not applicable: 1 | Clinuvel Pharmaceuticals Limited; Clinuvel Europe Limited | 2 |
| PT-141Compare research listing prices → | 10 | 1 | Phase 4: 2 · Phase 3: 3 · Phase 2: 4 · Phase 1: 1 | Palatin Technologies, Inc; AMAG Pharmaceuticals, Inc. | 6 |
| Thymosin Beta-4Compare research listing prices → | 9 | 1 | Phase 2: 8 · Phase 1: 1 | RegeneRx Biopharmaceuticals, Inc.; ReGenTree, LLC | 1 |
| PP405 | 2 | 1 | Phase 3: 1 · Phase 2: 1 | Pelage Pharmaceuticals, Inc. | 0 |
| GHK-CuCompare research listing prices → | 1 | 1 | Phase 2: 1 | Hudson Biotech | 0 |
| Melanotan-2Compare research listing prices → | 1 | 1 | Phase 2: 1 | Hudson Biotech | 2 |
| MOTS-cCompare research listing prices → | 1 | 1 | Phase 2: 1 | Hudson Biotech | 0 |
| TB-500 Fragment (17-23)Compare research listing prices → | 1 | 1 | Phase 2: 1 | Hudson Biotech | 0 |
| TestagenCompare research listing prices → | 1 | 1 | Phase 2: 1 | Transdermal Delivery Solutions Corp | 0 |
| VIPCompare research listing prices → | 7 | 0 | Phase 1: 1 · Not applicable: 6 | Danish Headache Center; Glostrup University Hospital, Copenhagen | 1 |
| TRH (Protirelin) | 6 | 0 | Phase 3: 1 · Phase 2: 2 · Phase 1: 1 · Not applicable: 2 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Memorial Sloan Kettering Cancer Center | 0 |
| Kisspeptin-10Compare research listing prices → | 5 | 0 | Phase 3: 3 · Phase 1: 2 | Quaid-e-Azam University; Ghulam Nabi | 3 |
| Acetyl Hexapeptide-3 (Argireline)Compare research listing prices → | 3 | 0 | Phase 2: 2 · Not applicable: 1 | National Institute of Neurological Disorders and Stroke (NINDS); University of California, Davis | 1 |
| ARA-290Compare research listing prices → | 2 | 0 | Phase 2: 2 | Araim Pharmaceuticals, Inc.; Claes-Göran Östenson | 3 |
| IpamorelinCompare research listing prices → | 2 | 0 | Phase 2: 2 | Helsinn Therapeutics (U.S.), Inc | 2 |
| LL-37Compare research listing prices → | 2 | 0 | Phase 2: 2 | Fakultas Kedokteran Universitas Indonesia; M.D. Anderson Cancer Center | 0 |
| CJC-1295 (DAC)Compare research listing prices → | 1 | 0 | Phase 2: 1 | ConjuChem | 2 |
| GonadorelinCompare research listing prices → | 1 | 0 | Phase 3: 1 | Hospital de Niños R. Gutierrez de Buenos Aires | 1 |
| Orforglipron CapsulesNot a peptide · listed by research suppliers | 40 | 20 | Phase 4: 2 · Phase 3: 27 · Phase 1: 11 | Eli Lilly and Company; Massachusetts General Hospital | 6 |
| L-CarnitineNot a peptide · listed by research suppliers | 40 | 16 | Phase 4: 6 · Phase 3: 5 · Phase 2: 13 · Phase 1: 1 · Early phase 1: 3 · Not applicable: 12 | Ain Shams University; Alexandria University | 0 |
| Methylene Blue SolutionNot a peptide · listed by research suppliersCompare research listing prices → | 40 | 12 | Phase 4: 1 · Phase 3: 9 · Phase 2: 6 · Phase 1: 3 · Early phase 1: 3 · Not applicable: 18 | Mashhad University of Medical Sciences; Wang wanxia | 2 |
| CagriSemaNot a peptide · listed by research suppliers | 29 | 11 | Phase 3: 19 · Phase 2: 4 · Phase 1: 6 | Novo Nordisk A/S | 5 |
| CerebrolysinNot a peptide · listed by research suppliersCompare research listing prices → | 40 | 8 | Phase 4: 13 · Phase 3: 7 · Phase 2: 9 · Phase 1: 1 · Early phase 1: 1 · Not applicable: 9 | Ever Neuro Pharma GmbH; Ain Shams University | 5 |
| NAD+Not a peptide · listed by research suppliersCompare research listing prices → | 7 | 3 | Phase 3: 1 · Phase 2: 1 · Early phase 1: 1 · Not applicable: 4 | AgelessRx; Nutraceuticals Research Institute | 1 |
| HCGNot a peptide · listed by research suppliersCompare research listing prices → | 25 | 2 | Phase 4: 7 · Phase 3: 4 · Phase 2: 4 · Early phase 1: 1 · Not applicable: 9 | Reproductive Medicine Associates of New Jersey; Universitair Ziekenhuis Brussel | 1 |
| Agomelatine PowderNot a peptide · listed by research suppliersCompare research listing prices → | 19 | 1 | Phase 4: 8 · Phase 3: 7 · Phase 2: 1 · Not applicable: 3 | Novartis; Novartis Pharmaceuticals | 5 |
| OstarineNot a peptide · listed by research suppliers | 17 | 1 | Phase 3: 4 · Phase 2: 12 · Phase 1: 1 | GTx; Veru Inc. | 0 |
| TB-500Not a peptide · listed by research suppliersCompare research listing prices → | 1 | 1 | Phase 2: 1 | Hudson Biotech | 0 |
| EnclomipheneNot a peptide · listed by research suppliersCompare research listing prices → | 22 | 0 | Phase 3: 9 · Phase 2: 4 · Phase 1: 9 | Repros Therapeutics Inc. | 3 |
| Tesofensine CapsulesNot a peptide · listed by research suppliersCompare research listing prices → | 9 | 0 | Phase 2: 8 · Phase 1: 1 | Saniona; NeuroSearch A/S | 5 |
| Fasoracetam PowderNot a peptide · listed by research suppliersCompare research listing prices → | 6 | 0 | Phase 3: 1 · Phase 2: 2 · Phase 1: 3 | Aevi Genomic Medicine, LLC, a Cerecor company | 1 |
| ACE-031Not a peptide · listed by research suppliersCompare research listing prices → | 4 | 0 | Phase 2: 2 · Phase 1: 2 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2 |
| AICARNot a peptide · listed by research suppliersCompare research listing prices → | 4 | 0 | Phase 3: 1 · Phase 2: 2 · Not applicable: 1 | Advancell - Advanced In Vitro Cell Technologies, S.A.; Baker Heart Research Institute | 3 |
| MK-677Not a peptide · listed by research suppliersCompare research listing prices → | 4 | 0 | Phase 2: 3 · Not applicable: 1 | University of Virginia; Bennett, Robert, M.D. | 4 |
| CardarineNot a peptide · listed by research suppliers | 3 | 0 | Phase 4: 1 · Phase 2: 1 · Not applicable: 1 | GlaxoSmithKline; The University of Western Australia | 0 |
| LGD-4033Not a peptide · listed by research suppliers | 1 | 0 | Phase 2: 1 | Viking Therapeutics, Inc. | 1 |
| Nefiracetam PowderNot a peptide · listed by research suppliersCompare research listing prices → | 1 | 0 | Phase 2: 1 | National Institute of Neurological Disorders and Stroke (NINDS) | 3 |
| Pramiracetam PowderNot a peptide · listed by research suppliersCompare research listing prices → | 1 | 0 | Phase 1: 1 | Abdulraheem Mohamed Gouda | 3 |
| RAD-140Not a peptide · listed by research suppliers | 1 | 0 | Phase 1: 1 | Stemline Therapeutics, Inc. | 0 |
Recently updated active studies
Recruiting, not yet recruiting, enrolling by invitation or active but not recruiting, most recently updated first. Check eligibility and locations on ClinicalTrials.gov.
Questions
Are peptides being tested in clinical trials?
Yes. PeptideTech has matched 853 ClinicalTrials.gov registrations across 54 tracked compounds in which the compound is a listed intervention; 287 are active or recruiting, 319 are phase 3 or 4, and 130 have posted results. Profiles with the most active registrations: Tirzepatide (38), Semaglutide (34), Mazdutide (24), Cagrilintide (16) and Eloralintide (15). A registration describes a protocol, not an outcome, and studies of an approved medicine do not concern research-labelled listings.
Source: ClinicalTrials.gov (U.S. National Library of Medicine)
How were these clinical trials matched?
Each registration lists the compound, or a reviewed development code for it, as an intervention on ClinicalTrials.gov. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded, and reviewed false matches are removed. Profiles keep up to 40 registrations, active studies first.
Can I take part in a peptide clinical trial?
Enrolment is decided by each study team against its eligibility criteria. Use the registration links to read a study’s status, locations and contacts on ClinicalTrials.gov. PeptideTech does not run, recruit for or recommend any study.
Related
Which peptides are FDA approved? · Research library: structures, identifiers and studies · Compare research listing prices